Gyre Therapeutics is expected to report a Q3 2026 consensus revenue of $32.4 million and an EPS loss of $0.14, while its current price of $14.85 sits well below the average analyst price target of $28.00. Investors are primarily focused on the commercial ramp-up of ETX-155 (Hydronidone) in China and its continued growth trajectory within the fibrosis market.
Recent quarters have shown steady progress in patient enrollment for U.S. clinical trials, and analysts are looking for updates on the Phase 2 regulatory timeline for metabolic dysfunction-associated steatohepatitis (MASH). Management's ability to maintain high gross margins while expanding the sales force remains a critical component of the bull case.